Several doctors and healthcare providers are adopting the methods of polypharmacology to develop new drugs for mental disorders. These methods are providing better outcomes in patients as compared to single-target drugs in the schizophrenia drugs market.
Likewise, multi-target drugs are emerging as an effective alternative to treat polygenic diseases, including schizophrenia. As such, the second-generation drugs market is estimated to reach ~US$ 11.1 billion by the year 2027; the highest amongst all drug classes in the schizophrenia drugs landscape. These second-generation drugs, i.e. atypical antipsychotics, target a number of aminergic G-protein coupled receptors (GPCRs) to treat complex pathomechanisms of schizophrenia.
Pharmaceutical companies are increasing research & development related to the schizophrenia drugs market to develop drugs that are beyond the dopaminergic hypothesis of schizophrenia and beyond monoamine G protein coupled receptors (GPCRs). They are increasing their production capacities of dopamine antagonists and drugs meant to effectively control the symptoms of schizophrenia and improve patient quality of life. Manufacturers in the schizophrenia drugs market are also turning towards other second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients.
There is the growing need for improved schizophrenia drugs, as psychiatric disorders lead to disorders of the whole body. That is why, healthcare companies are innovating on live cellular function as a model to treat schizophrenia. Manufacturers in the schizophrenia drugs market are using high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs. This drug 'repurposing' strategy serves as a cost-effective and time-saving alternative for the development of new schizophrenia drugs that can be supplied to small-scale clinics and other healthcare providers.
The live cellular function model helps manufacturers develop new potential drugs at competitive costs, and acts as an efficient alternative to develop the drugs in a significantly less amount of time. The high-content single-cell screening process helps companies test existing psychiatric treatments on patient blood cells and predict the effectiveness of the new schizophrenia drug, depending upon the health condition of each individual.
This first-of-its-kind process will help healthcare companies overcome the limitations of first-line treatments, as these treatments have been performing poorly in most patients.
One of the major challenges that restricts healthcare companies from developing novel drugs for the schizophrenia drugs market is the lack of sample-based tests. Since doctors cannot take brain tissue samples from patients like they do in a biopsy on a cancer tumor elsewhere in the body, it is challenging for researchers to study the root causes of schizophrenia. This becomes a hurdle for doctors and researchers as to what to target in order to design novel neuropsychiatric drugs. As such, healthcare companies are collaborating with doctors and researchers to study the live blood cells of patients with mental health disorders. These blood cells help researchers identify potential targets for drug discovery.
Companies are increasing focus on the study of human blood cells, as these cells are closely associated with the central nervous system. This makes blood cells an ideal environment to test potential new drugs.
Analysts’ Viewpoint
The schizophrenia drugs market is expected to grow the fastest in Asia Pacific on an account of the demand for less-invasive oral drugs that are anticipated to reach ~US$ 10.8 billion by 2027. Healthcare companies are increasing research on primary cells from patients to gain high success rates in the discovery of effective drugs. They are also innovating on antipsychotic drugs, as these drugs provide a range of tools to explore brain function in health and mental disorders. However, antipsychotic drugs have a high risk of disrupting the extrapyramidal function in patients. Also, these drugs do not have enough clinical evidence to prove their effectiveness in the development of new compounds in drugs.
As such, healthcare companies are increasing research & development to closely understand the effects of antipsychotic drugs on the central dopamine homeostasis of patients. Companies operating in the schizophrenia drugs market should focus on new models of preventive treatments of schizophrenia, such as the animal model and stem cell technology, for improved schizophrenia drug screenings.
Schizophrenia Drugs Market: Overview
Schizophrenia Drugs Market: Key Trends
Schizophrenia Drugs Market: Competition
FDA Approval and Product Expansion
Mergers & Acquisitions to Strengthen Market Position
Global Schizophrenia Drugs Market – Segmentation
|
Drug Class |
First Generation Drugs Second Generation Drugs Third Generation Drugs |
|
Route of Administration |
Injectable Oral |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Schizophrenia drugs market is projected to reach ~US$ 15.5 Bn by 2027
Schizophrenia drugs market expand at a CAGR of ~4% from 2019 to 2027
Schizophrenia drugs market is driven by rise in the prevalence of schizophrenia and launch of new schizophrenia drugs
The second generation drugs segment dominated the global schizophrenia drugs market, owing to their low risk of neurological side effects
Key players in the schizophrenia drugs market include Janssen Global Services, LLC (Johnson & Johnson), ALLERGAN, Pfizer Inc., and Otsuka Holdings Co., Ltd., Pfizer, Inc. and Hospira, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Schizophrenia Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Schizophrenia Drugs Introduction
4.1.2. Market Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027
4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast
5. Key Insights
5.1. Pipeline Analysis: Schizophrenia Drugs
5.2. Value Chain Analysis
5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027
6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definitions
6.2. Key Findings / Developments
6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.3.1. First Generation Drugs
6.3.2. Second Generation Drugs
6.3.3. Third Generation Drugs
6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class
7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definitions
7.2. Key Findings / Developments
7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
7.3.1. Injectable
7.3.2. Oral
7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration
8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Schizophrenia Drugs Market Attractiveness, by Region
9. North America Schizophrenia Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. First Generation Drugs
9.2.2. Second Generation Drugs
9.2.3. Third Generation Drugs
9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
9.3.1. Injectable
9.3.2. Oral
9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Schizophrenia Drugs Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Route of Administration
9.5.3. By Country
10. Europe Schizophrenia Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. First Generation Drugs
10.2.2. Second Generation Drugs
10.2.3. Third Generation Drugs
10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
10.3.1. Injectable
10.3.2. Oral
10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Route of Administration
10.5.3. By Country/Sub-region
11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. First Generation Drugs
11.2.2. Second Generation Drugs
11.2.3. Third Generation Drugs
11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
11.3.1. Injectable
11.3.2. Oral
11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Route of Administration
11.5.3. By Country/Sub-region
12. Latin America Schizophrenia Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. First Generation Drugs
12.2.2. Second Generation Drugs
12.2.3. Third Generation Drugs
12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
12.3.1. Injectable
12.3.2. Oral
12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Country/Sub-region
13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. First Generation Drugs
13.2.2. Second Generation Drugs
13.2.3. Third Generation Drugs
13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
13.3.1. Injectable
13.3.2. Oral
13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Route of Administration
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)
14.2. Company Profiles
14.2.1. Allergan
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Financial Overview
14.2.1.3. Product Portfolio
14.2.1.4. SWOT Analysis
14.2.1.5. Strategic Overview
14.2.2. Otsuka Holdings Co., Ltd
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Financial Overview
14.2.2.3. Product Portfolio
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Janssen Pharmaceutica (Johnson & Johnson)
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Financial Overview
14.2.3.3. Product Portfolio
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Pfizer Inc.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Financial Overview
14.2.4.3. Product Portfolio
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Maynepharma
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Financial Overview
14.2.5.3. Product Portfolio
14.2.5.4. SWOT Analysis
14.2.5.5. Strategic Overview
14.2.6. Vanda Pharmaceuticals Inc.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Financial Overview
14.2.6.3. Product Portfolio
14.2.6.4. SWOT Analysis
14.2.6.5. Strategic Overview
14.2.7. Sumitomo Dainippon Pharma
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Financial Overview
14.2.7.3. Product Portfolio
14.2.7.4. SWOT Analysis
14.2.7.5. Strategic Overview
14.2.8. Eli Lilly & Co.
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Financial Overview
14.2.8.3. Product Portfolio
14.2.8.4. SWOT Analysis
14.2.8.5. Strategic Overview
14.2.9. AstraZeneca Plc
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Financial Overview
14.2.9.3. Product Portfolio
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
List of Tables
Table 01: Pipeline Analysis
Table 02: Depression Drugs Sales Analysis, 2015–2017
Table 03: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 05: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region, 2017–2027
Table 06: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027
Table 07: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 08: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 09: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 10: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 11: Europe Schizophrenia drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 12: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 14: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 15: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 16: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 17: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 18: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 20: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
List of Figures
Figure 01: Global Schizophrenia Drugs Market Analysis, by Route of Administration
Figure 02: Global Schizophrenia Drugs Market Analysis, by Drug Class
Figure 03: Global Schizophrenia Drugs Market Analysis, by Region
Figure 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 05: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018
Figure 06: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018
Figure 07: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018
Figure 08: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, 2017–2027
Figure 09: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 10: Global Schizophrenia Drugs Market Revenue (US$ Mn), by First Generation Drugs, 2017–2027
Figure 11: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Second Generation Drugs, 2017–2027
Figure 12: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Third Generation Drugs, 2017–2027
Figure 13: Global Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 14: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 15: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Oral Route of Administration, 2017–2027
Figure 16: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Injectable Route of Administration, 2017–2027
Figure 17: Global Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 18: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018 and 2027
Figure 19: Global Schizophrenia Drugs Market Attractiveness Analysis, by Region, 2019–2027
Figure 20: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 21: North America Schizophrenia Drugs Market Attractiveness Analysis, by Country, 2019–2027
Figure 22: North America Schizophrenia Drugs Market Value Share Analysis, by Country, 2018 and 2027
Figure 23: North America Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 24: North America Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 25: North America Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 26: North America Schizophrenia drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 27: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 28: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 29: Europe Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 30: Europe Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 31: Europe Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 32: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 33: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 34: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 35: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 36: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 37: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 38: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 39: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 40: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 41: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 42: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 43: Latin America Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 44: Latin America Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 45: Latin America Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 46: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 47: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 48: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 49: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 50: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 51: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 52: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 53: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 54: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 55: Global Schizophrenia drugs Market Analysis, by Company Ranking, 2018
Figure 56: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018
Figure 57: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018
Figure 58: Johnson & Johnson Breakdown of Net Sales, by Region, 2018
Figure 59: Johnson & Johnson Breakdown of Net Sales, by Business Segment, 2018
Figure 60: Allergan Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018
Figure 61: Allergan R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2018
Figure 62: Allergan Breakdown of Net Sales, by Business Segment (%), 2018
Figure 63: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016–2018
Figure 64: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 65: Otsuka Holdings Co. Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014–2017
Figure 66: Otsuka Holdings Co. Ltd. R&D Spending and Sales & Distribution Spending (US$ Bn) – Company Level, 2016–2017
Figure 67: Otsuka Holdings Co. Ltd. Breakdown of Net Sales, by Region (Company Level), 2017
Figure 68: Otsuka Holdings Co. Ltd. Breakdown of Net Sales (Overall Company Level), 2017
Figure 69: Eli Lily and Company Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2016–2018
Figure 70: Eli Lily and Company Breakdown of Net Sales, by Neuroscience Level, 2018
Figure 71: Eli Lily and Company Breakdown of Net Sales, by Region, 2018
Figure 72: AstraZeneca Plc. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014–2017
Figure 73: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018
Figure 74: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018 (%)
Figure 75: Mayne Pharma Group Limited Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016-2018
Figure 76: Mayne Pharma Group Limited Breakdown of Net Sales (%), by Region, 2018
Figure 77: Sumitomo Dainippon Pharma Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2017
Figure 78: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Business Segment, 2017
Figure 79: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Region, 2017
Figure 80: Vanda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Schizophrenia Drugs Market
